Budha, N. R., Leabman, M., Jin, J. Y., Wada, D. R., Baruch, A., Peng, K., . . . Davis, J. D. (2015). Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9. AAPS J.
Stile di citazione ChicagoBudha, Nageshwar R., Maya Leabman, Jin Y. Jin, D. Russell Wada, Amos Baruch, Kun Peng, Whittemore G. Tingley, e John D. Davis. "Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9." AAPS J 2015.
Citazione MLABudha, Nageshwar R., et al. "Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9." AAPS J 2015.